Stock Movers: Sainsbury's Sales Surge, Zealand Pharma Gains on New Drug Potential, UK House Prices Dip

Sainsbury's Sales Growth

• 🛒 Sainsbury's reported strong sales growth of around 5% in the 16 weeks to June 21st, exceeding analyst expectations.
• 📈 The UK supermarket chain achieved its highest market share in nearly a decade, demonstrating resilience amidst sector-wide concerns about discounting.
• 💡 The success is partly attributed to its loyalty program, Nectar, which has helped maintain customer volumes despite price competition.

Zealand Pharma's Promising Weight Loss Drug

• 🔬 Zealand Pharma shares rose significantly after BNP Paribas Exane initiated coverage with an 'outperform' recommendation.
• 💊 Analysts highlight Zealand Pharma's new drug, amalain, which mimics appetite suppressants and has the potential to compete with major GLP-1 drugs like Wegovy and Mounjaro.
• 💰 The drug is projected to capture an 8% share of the global obesity market, estimated to be worth hundreds of billions in the coming years.

UK Housing Market Decline

• 🏠 UK house prices experienced their steepest fall in over two years in June, with the average home price declining to £271,619 according to Nationwide Building Society.
• 📉 This downturn is impacting housebuilder stocks, with Taylor Wimpey, Barratt Developments, Vistry, and Bellway all seeing declines.
• ⚠️ Analysts suggest the recent increase in transaction taxes in April may have distorted the market, though underlying demand for homes might be stronger due to falling mortgage rates.